Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 357

1.

Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond.

Pertwee RG.

Addict Biol. 2008 Jun;13(2):147-59. doi: 10.1111/j.1369-1600.2008.00108.x. Review.

PMID:
18482430
2.

Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist.

Justinová Z, Ferré S, Redhi GH, Mascia P, Stroik J, Quarta D, Yasar S, Müller CE, Franco R, Goldberg SR.

Addict Biol. 2011 Jul;16(3):405-15. doi: 10.1111/j.1369-1600.2010.00258.x. Epub 2010 Nov 4.

3.

Why do cannabinoid receptors have more than one endogenous ligand?

Di Marzo V, De Petrocellis L.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3216-28. doi: 10.1098/rstb.2011.0382. Review.

4.

Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors.

Nader J, Rapino C, Gennequin B, Chavant F, Francheteau M, Makriyannis A, Duranti A, Maccarrone M, Solinas M, Thiriet N.

Neuropharmacology. 2014 Dec;87:214-21. doi: 10.1016/j.neuropharm.2014.03.014. Epub 2014 Apr 5.

5.

Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.

McCollum L, Howlett AC, Mukhopadhyay S.

J Pharmacol Exp Ther. 2007 Jun;321(3):930-7. Epub 2007 Mar 22.

6.

Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.

Laprairie RB, Bagher AM, Kelly ME, Dupré DJ, Denovan-Wright EM.

J Biol Chem. 2014 Sep 5;289(36):24845-62. doi: 10.1074/jbc.M114.557025. Epub 2014 Jul 18.

7.

A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.

Chiba T, Ueno S, Obara Y, Nakahata N.

J Pharm Pharmacol. 2011 May;63(5):636-47. doi: 10.1111/j.2042-7158.2011.01250.x. Epub 2011 Mar 28.

PMID:
21492165
8.

Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects.

Ellgren M, Artmann A, Tkalych O, Gupta A, Hansen HS, Hansen SH, Devi LA, Hurd YL.

Eur Neuropsychopharmacol. 2008 Nov;18(11):826-34. doi: 10.1016/j.euroneuro.2008.06.009.

9.

Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.

Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, Shohami E, Spatz M.

Brain Res Mol Brain Res. 2004 Dec 6;132(1):87-92.

PMID:
15548432
10.

Attenuation of allergic contact dermatitis through the endocannabinoid system.

Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, Starowicz K, Steuder R, Schlicker E, Cravatt B, Mechoulam R, Buettner R, Werner S, Di Marzo V, Tüting T, Zimmer A.

Science. 2007 Jun 8;316(5830):1494-7.

11.

The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.

Sharir H, Console-Bram L, Mundy C, Popoff SN, Kapur A, Abood ME.

J Neuroimmune Pharmacol. 2012 Dec;7(4):856-65. doi: 10.1007/s11481-012-9351-6. Epub 2012 Mar 28.

12.

Inhibitory CB1 and activating/desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin.

Engel MA, Izydorczyk I, Mueller-Tribbensee SM, Becker C, Neurath MF, Reeh PW.

Neuropeptides. 2011 Jun;45(3):229-37. doi: 10.1016/j.npep.2011.03.005. Epub 2011 Apr 22.

PMID:
21514666
13.

Involvement of the endocannabinoid system in periodontal healing.

Kozono S, Matsuyama T, Biwasa KK, Kawahara K, Nakajima Y, Yoshimoto T, Yonamine Y, Kadomatsu H, Tancharoen S, Hashiguchi T, Noguchi K, Maruyama I.

Biochem Biophys Res Commun. 2010 Apr 16;394(4):928-33. doi: 10.1016/j.bbrc.2010.03.080. Epub 2010 Mar 15.

PMID:
20233580
14.

Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors.

Scutt A, Williamson EM.

Calcif Tissue Int. 2007 Jan;80(1):50-9. Epub 2007 Jan 4.

PMID:
17205329
15.

Endocannabinoids selectively enhance sweet taste.

Yoshida R, Ohkuri T, Jyotaki M, Yasuo T, Horio N, Yasumatsu K, Sanematsu K, Shigemura N, Yamamoto T, Margolskee RF, Ninomiya Y.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):935-9. doi: 10.1073/pnas.0912048107. Epub 2009 Dec 22.

16.

Cannabinoids and brain injury: therapeutic implications.

Mechoulam R, Panikashvili D, Shohami E.

Trends Mol Med. 2002 Feb;8(2):58-61.

PMID:
11815270
17.

An introduction to the endocannabinoid system: from the early to the latest concepts.

De Petrocellis L, Di Marzo V.

Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):1-15. doi: 10.1016/j.beem.2008.10.013. Review.

PMID:
19285257
18.

The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.

Di Marzo V.

Pharmacol Res. 2009 Aug;60(2):77-84. doi: 10.1016/j.phrs.2009.02.010. Epub 2009 Mar 4. Review.

PMID:
19559360
19.

Pharmacological actions of cannabinoids.

Pertwee RG.

Handb Exp Pharmacol. 2005;(168):1-51. Review.

PMID:
16596770
20.

Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors.

Eisenstein TK, Meissler JJ, Wilson Q, Gaughan JP, Adler MW.

J Neuroimmunol. 2007 Sep;189(1-2):17-22. Epub 2007 Jul 19.

Supplemental Content

Support Center